Skip to content

Cardioprotective effect of Saffron Total-glycoside Tablet in patients with breast cancer receiving anthracycline-based chemotherapy: a multicenter, randomized, parallel, double-blind placebo clinical trial

Cardioprotective effect of Saffron Total-glycoside Tablet in patients with breast cancer receiving anthracycline-based chemotherapy: a multicenter, randomized, parallel, double-blind placebo clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100004507
Enrollment
Unknown
Registered
2020-12-19
Start date
2021-06-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Heart Failure, Cardiotoxicity

Interventions

Sponsors

Guang'anmen Hospital, Chinese Academy of traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Female; 2. Patients aged 18-70 years; 3. Definite diagnosis of primary breast cancer; 4. Patients who are ready to receive anthracycline treatment, and the estimated cumulative dose is more than or equal to 240 mg / m2; 5. Patients who have not received bilateral / unilateral chest radiotherapy in the past; 6. Patients with Karnofsky score >= 60; 7. Patients with an estimated survival time of more than 6 months; 8. Randomly assigned patients; 9. Patients who voluntarily participated in the trial and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients using cardiac drugs within one month, such as angiotensin converting enzyme inhibitors, angiotensin receptor blockers, diuretics, ß - blockers, aldosterone receptor antagonists; 2. Patients diagnosed with cardiomyopathy (ischemic, dilative, restrictive or hypertrophic), moderate or severe aortic and / or mitral valve disease; 3. Patients with systolic blood pressure 180 mmHg; 4. Patients with chronic kidney disease whose EGFR 5.5mmol/l; 6. Patients with severe liver failure; 7. Patients who have used anthracyclines in the past and cannot trace the dosage of drugs; 8. Pregnant and lactating women; 9. Patients who are allergic to the components of the study drug or have contraindications to the use of the study drug; 10. Patients currently participating in clinical trials of other drugs or external therapies.

Design outcomes

Primary

MeasureTime frame
Prevention of systolic dysfunction in patients undergoing chemotherapy with anthracycline. Systolic dysfunction is characterized by a 10%(if the baseline LVEF = 50%) or 5%(if the baseline LVEF< 50%) drop in ejection fraction of left ventricle compared with baseline.;

Secondary

MeasureTime frame
cTnI;NT-pro-BNP;

Countries

China

Contacts

Public ContactYanwei Xing

Guang'anmen Hospital, Chinese Academy of traditional Chinese Medicine

xingyanwei12345@163.com+86 18514733206

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026